Company Overview
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels designed for applications including wound care, medical diagnostics, transdermal drug delivery, and cosmetics within the United States market. The company operates within the Healthcare sector, specifically in the Medical Instruments & Supplies industry, positioning it as a provider of specialized medical consumables and diagnostic materials. As a small-cap entity, the company holds a market capitalization of $5.37M and employs 19 individuals to support its manufacturing and sales operations. Its annual revenue for the trailing twelve months stands at $11.67M, indicating a relatively modest scale typical of niche medical device manufacturers that focus on specialized polymer technologies rather than broad-market volume. This revenue level suggests the company is an established player in its specific vertical but lacks the massive scale of large-cap healthcare conglomerates, resulting in a market cap that reflects its current operational footprint and limited public investor interest.
Financial Health
The company reported revenue of $11.67M over the trailing twelve months, yet it generated a net income of $-2,880,000 and an EBITDA of $-2,533,000. The substantial gap between the $11.67M revenue and the significant net loss reveals a cost structure where operating expenses heavily outweigh gross profits, preventing the realization of profitability despite substantial sales volume. Free cash flow stands at $-1,494,875, which indicates that the company is burning cash rather than generating liquidity, thereby limiting its financial flexibility to fund internal expansion or weather economic downturns without external capital injections. Profitability metrics are further eroded by a gross margin of 40.8%, an operating margin of -24.7%, and a profit margin of -24.7%, illustrating that while the product has inherent value, overhead costs and perhaps R&D or sales expenses are consuming nearly a quarter of every dollar earned. On the balance sheet, the company holds $938,000 in cash against $3.19M in debt, creating a leverage environment highlighted by a debt-to-equity ratio of 57.24, which signifies a highly leveraged position where debt obligations significantly exceed equity capital. Liquidity for short-term obligations is supported by a current ratio of 1.69, suggesting the company possesses sufficient current assets to cover its current liabilities, though the margin of safety is not excessive given the negative earnings environment. Return on equity is -52.8% and return on assets is -16.8%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.
Valuation Assessment
Valuation metrics for NEXGEL present a complex picture given its unprofitable status, with a trailing P/E ratio of N/A and a forward P/E of -11.00. The discrepancy between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing in a trajectory of continued negative earnings or significant restructuring costs rather than immediate profitability. The price-to-book ratio is 1.04, indicating that the market values the company at approximately equal to its book value, suggesting no significant premium or discount relative to its net asset position. Alternative valuation metrics such as a price-to-sales ratio of 0.46 and an EV/EBITDA of -3.17 suggest the market is valuing the firm primarily on its revenue generation capabilities and existing asset base rather than earnings power. Price action shows a 52-week high of $3.25 and a 52-week low of $0.65, and assuming the current trading price aligns with typical small-cap volatility patterns in this sector, the stock often trades well below its 52-week high, reflecting the risk premium associated with its negative earnings and high debt load. The stock exhibits a beta of 0.62, meaning its price volatility is lower than the broader market, suggesting that NXGL moves less aggressively than large-cap indices, which may offer some downside protection but also limits upside potential during market rallies.
Growth & Income
Revenue growth year-over-year is recorded at -0.2%, while earnings growth is N/A due to the company's persistent losses. The stagnation in revenue growth coupled with the absence of positive earnings growth implies that the company is struggling to expand its top line and has yet to achieve a path toward consistent profitability. As a non-dividend payer, the company offers a dividend yield of N/A with a payout ratio of 0.0%, indicating that it retains all earnings—or rather, all losses—to fund operations and debt servicing rather than distributing income to shareholders. This lack of a dividend payout aligns with the company's reinvestment strategy, although in this context, the reinvestment is necessary to cover operating deficits rather than fuel explosive growth. The overall growth and income profile is characterized by flat-to-negative revenue expansion, significant negative earnings, and a complete absence of dividend income, positioning the asset as a high-risk, high-volatility investment suitable only for portfolios tolerant of deep losses and capital erosion.